

Adam P Dicker

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7531820/adam-p-dicker-publications-by-year.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

290
papers

12,703
citations

58
h-index

101
g-index

305
ext. papers

14,967
ext. citations

5.3
avg, IF

6.17
L-index

#	Paper	IF	Citations
290	Subpathologies and genomic classifier for treatment individualization of post-prostatectomy radiotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022 , 40, 5.e1-5.e13	2.8	
289	A Pilot Feasibility Study of Digital Health Coaching for Men With Prostate Cancer.. <i>JCO Oncology Practice</i> , 2022 , OP2100712	2.3	
288	Coeliac plexus radiosurgery for pain management in patients with advanced cancer : study protocol for a phase II clinical trial.. <i>BMJ Open</i> , 2022 , 12, e050169	3	
287	Variation in Molecularly Defined Prostate Tumor Subtypes by Self-identified Race. <i>European Urology Open Science</i> , 2022 , 40, 19-26	0.9	0
286	NIMG-22. PREDICTION OF GLIOBLASTOMA CELLULAR INFILTRATION AND RECURRENCE USING MACHINE LEARNING AND MULTI-PARAMETRIC MRI ANALYSIS: RESULTS FROM THE MULTI-INSTITUTIONAL RESPOND CONSORTIUM. <i>Neuro-Oncology</i> , 2021 , 23, vi132-vi133	1	1
285	Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2021 , 7, 544-552	13.4	17
284	Next-Generation Implementation of Chimeric Antigen Receptor T-Cell Therapy Using Digital Health. <i>JCO Clinical Cancer Informatics</i> , 2021 , 5, 668-678	5.2	3
283	Immune Checkpoint Inhibitor Therapy Toxicities. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 326, 87	27.4	0
282	A Pilot Trial Using Telemedicine in Radiation Oncology: The Future of Health Care Is Virtual. <i>Telemedicine Reports</i> , 2021 , 2, 171-178	2	0
281	Digital Literacy at an Urban Cancer Center: Implications for Technology Use and Vulnerable Patients. <i>JCO Clinical Cancer Informatics</i> , 2021 , 5, 872-880	5.2	4
280	Machine Learning Using Multiparametric Magnetic Resonance Imaging Radiomic Feature Analysis to Predict Ki-67 in World Health Organization Grade I Meningiomas. <i>Neurosurgery</i> , 2021 , 89, 928-936	3.2	1
279	BRCA1 Protein Expression Predicts Survival in Glioblastoma Patients from an NRG Oncology RTOG Cohort. <i>Oncology</i> , 2021 , 99, 580-588	3.6	1
278	NIMG-39. RADIOMIC ANALYSIS FOR NON-INVASIVE IN VIVO PROGNOSTIC STRATIFICATION OF DE NOVO GLIOBLASTOMA PATIENTS: A MULTI-INSTITUTIONAL EVALUATION FOR GENERALIZABILITY IN THE RESPOND CONSORTIUM. <i>Neuro-Oncology</i> , 2021 , 23, vi137-vi137	1	
277	Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2798-2811	2.2	80
276	AI-based prognostic imaging biomarkers for precision neuro-oncology: the ReSPOND consortium. <i>Neuro-Oncology</i> , 2020 , 22, 886-888	1	14
275	Histopathology-validated machine learning radiographic biomarker for noninvasive discrimination between true progression and pseudo-progression in glioblastoma. <i>Cancer</i> , 2020 , 126, 2625-2636	6.4	30
274	Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 650-659	13.4	297

273	Innovations in research and clinical care using patient-generated health data. <i>Ca-A Cancer Journal for Clinicians</i> , 2020 , 70, 182-199	220.7	36
272	Development of a Functional Assessment of Chronic Illness Therapy item library and primary symptom list for the assessment of patient-reported adverse events associated with immune checkpoint modulators. <i>Journal of Cancer Metastasis and Treatment</i> , 2020 , 6,	3.8	2
271	Utilizing Digital Health to Collect Electronic Patient-Reported Outcomes in Prostate Cancer: Single-Arm Pilot Trial. <i>Journal of Medical Internet Research</i> , 2020 , 22, e12689	7.6	14
270	Use of a Cancer Registry to Evaluate Patient-Reported Outcomes of Immune Checkpoint Inhibitors. <i>Cancers</i> , 2020 , 13,	6.6	3
269	Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy. <i>Prostate Cancer and Prostatic Diseases</i> , 2020 , 23, 295-302	6.2	17
268	Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 83-93	2.8	8
267	Provider Engagement in Radiation Oncology Data Science: Workshop Report. <i>JCO Clinical Cancer Informatics</i> , 2020 , 4, 700-710	5.2	
266	Tumor-Derived Extracellular Vesicles Require β Integrins to Promote Anchorage-Independent Growth. <i>IScience</i> , 2019 , 14, 199-209	6.1	18
265	Telemedicine Training in Undergraduate Medical Education: Mixed-Methods Review. <i>JMIR Medical Education</i> , 2019 , 5, e12515	5	105
264	Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 6721-6730	12.9	35
263	Clinical Outcome Assessments Toolbox for Radiopharmaceuticals. <i>Frontiers in Oncology</i> , 2019 , 9, 1028	5.3	1
262	Common error pathways seen in the RO-ILS data that demonstrate opportunities for improving treatment safety. <i>Practical Radiation Oncology</i> , 2018 , 8, 123-132	2.8	27
261	Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology. <i>Lancet Oncology, The</i> , 2018 , 19, e240-e251	21.7	66
260	Improvement in Therapeutic Efficacy and Reduction in Cellular Toxicity: Introduction of a Novel Anti-PSMA-Conjugated Hybrid Antiandrogen Nanoparticle. <i>Molecular Pharmaceutics</i> , 2018 , 15, 1778-1790	5.6	2
259	PD-1 Modulates Radiation-Induced Cardiac Toxicity through Cytotoxic T Lymphocytes. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 510-520	8.9	41
258	Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 1402-1414	12.9	21
257	Targeting Myeloid-derived Suppressor Cells and Programmed Death Ligand 1 Confers Therapeutic Advantage of Ablative Hypofractionated Radiation Therapy Compared With Conventional Fractionated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 101, 74-87	4	56
256	The Impact of Radiation on the Tumor Microenvironment: Effect of Dose and Fractionation Schedules. <i>Cancer Growth and Metastasis</i> , 2018 , 11, 1179064418761639		69

255	Impact of Radiation Therapy Dose Escalation on Prostate Cancer Outcomes and Toxicities. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018 , 41, 409-415	2.7	38
254	Decision Support and Shared Decision Making About Active Surveillance Versus Active Treatment Among Men Diagnosed with Low-Risk Prostate Cancer: a Pilot Study. <i>Journal of Cancer Education</i> , 2018 , 33, 180-185	1.8	11
253	Onco-metabolism: defining the prognostic significance of obesity and diabetes in women with brain metastases from breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018 , 172, 221-230	4.4	12
252	Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy. <i>European Urology</i> , 2018 , 74, 107-114	10.2	36
251	Blockade of Tumor-Expressed PD-1 promotes lung cancer growth. <i>Oncotmunology</i> , 2018 , 7, e1408747	7.2	63
250	Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program. <i>Oncologist</i> , 2018 , 23, 193-202	5.7	51
249	Clinical Integration of Digital Solutions in Health Care: An Overview of the Current Landscape of Digital Technologies in Cancer Care. <i>JCO Clinical Cancer Informatics</i> , 2018 , 2, 1-9	5.2	49
248	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. <i>Journal of Clinical Oncology</i> , 2018 , 36, 414-424	2.2	107
247	Assessing the Training and Research Environment for Genomics, Bioinformatics, and Immunology in Radiation Oncology. <i>JCO Clinical Cancer Informatics</i> , 2018 , 2, 1-9	5.2	5
246	Intersection of Digital Health and Oncology. <i>JCO Clinical Cancer Informatics</i> , 2018 , 2, 1-4	5.2	8
245	PARP-1 regulates DNA repair factor availability. <i>EMBO Molecular Medicine</i> , 2018 , 10,	12	35
244	Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy. <i>Clinical Cancer Research</i> , 2018 , 24, 3908-3916	12.9	10
243	Cost-effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, e299-309 ²⁰	3.3	20
242	Comparison of Online 6 Degree-of-Freedom Image Registration of Varian TrueBeam Cone-Beam CT and BrainLab ExacTrac X-Ray for Intracranial Radiosurgery. <i>Technology in Cancer Research and Treatment</i> , 2017 , 16, 339-343	2.7	6
241	IGFBP3 Modulates Lung Tumorigenesis and Cell Growth through IGF1 Signaling. <i>Molecular Cancer Research</i> , 2017 , 15, 896-904	6.6	33
240	RB Loss Promotes Prostate Cancer Metastasis. <i>Cancer Research</i> , 2017 , 77, 982-995	10.1	47
239	Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1982-1990	2.2	56
238	Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment. <i>Journal of Clinical Oncology</i> , 2017 , 35, 139-140	2.2	14

237	Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1991-1998	2.2	127
236	Randomized Phase II Study of Preoperative Chemoradiotherapy ± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non-Small Cell Lung Cancer: NRG Oncology RTOG 0839. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1413-1420	8.9	19
235	Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2017 , 3, 1520-1528	13.4	107
234	A phase II randomized trial of Observation versus stereotactic ablative Radiation for Oligometastatic prostate Cancer (ORIOLE). <i>BMC Cancer</i> , 2017 , 17, 453	4.8	60
233	Molecular Analysis of Low Grade Prostate Cancer Using a Genomic Classifier of Metastatic Potential. <i>Journal of Urology</i> , 2017 , 197, 122-128	2.5	29
232	mHealth: Mobile Technologies to Virtually Bring the Patient Into an Oncology Practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017 , 37, 144-154	7.1	10
231	A phase II randomized trial of observation versus stereotactic ablative radiation for oligometastatic prostate cancer (ORIOLE).. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS5094-TPS5094	2.2	
230	Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. <i>Lancet Oncology</i> , 2016 , 17, 1612-1620	21.7	124
229	The Missing Pieces in Reporting of Randomized Controlled Trials of External Beam Radiation Therapy Dose Escalation for Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016 , 39, 321-6	2.7	7
228	Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2925-34	2.2	384
227	Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy. <i>European Urology</i> , 2016 , 70, 588-596	10.2	56
226	Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. <i>JAMA Oncology</i> , 2016 , 2, 471-80	13.4	38
225	Racial Variations in Prostate Cancer Molecular Subtypes and Androgen Receptor Signaling Reflect Anatomic Tumor Location. <i>European Urology</i> , 2016 , 70, 14-17	10.2	56
224	Phase I trial of panobinostat and fractionated stereotactic re-irradiation therapy for recurrent high grade gliomas. <i>Journal of Neuro-Oncology</i> , 2016 , 127, 535-9	4.8	30
223	Quality and Reporting Accuracy of Phase 1 Drug Radiation Clinical Trials. <i>JAMA Oncology</i> , 2016 , 2, 390-1	13.4	
222	α integrin- and JNK-dependent tumor growth upon hypofractionated radiation. <i>Oncotarget</i> , 2016 , 7, 52618-52630	3.3	5
221	Plan Quality and Treatment Efficiency for Radiosurgery to Multiple Brain Metastases: Non-Coplanar RapidArc vs. Gamma Knife. <i>Frontiers in Oncology</i> , 2016 , 6, 26	5.3	45
220	Stereotactic Body Radiation Therapy Delivery in a Genetically Engineered Mouse Model of Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 96, 529-37	4	12

219	American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2563-77	2.2	599
218	Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes. <i>European Urology</i> , 2015 , 68, 555-67	10.2	100
217	X-ray Diffraction Investigations of Shape Memory NiTi Wire. <i>Journal of Materials Engineering and Performance</i> , 2015 , 24, 3038-3048	1.6	4
216	Quantifying Unnecessary Normal Tissue Complication Risks due to Suboptimal Planning: A Secondary Study of RTOG 0126. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 92, 228-35	4	79
215	Social Media and Oncology: The Past, Present, and Future of Electronic Communication Between Physician and Patient. <i>Seminars in Oncology</i> , 2015 , 42, 764-71	5.5	33
214	Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2789-96	2.2	99
213	African American men with low-grade prostate cancer have increased disease recurrence after prostatectomy compared with Caucasian men. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 70.e15-22	2.8	29
212	Assessing adverse events of postprostatectomy radiation therapy for prostate cancer: evaluation of outcomes in the Regione Emilia-Romagna, Italy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 91, 752-9	4	8
211	American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment. <i>Journal of Clinical Oncology</i> , 2015 , 33, 278-84	2.2	84
210	Novel actions of next-generation taxanes benefit advanced stages of prostate cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 795-807	12.9	75
209	Adjuvant versus salvage radiation therapy for prostate cancer patients with adverse pathologic features: comparative analysis of long-term outcomes. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015 , 38, 55-60	2.7	20
208	Reply to C.G. Rusthoven et al. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1990-1	2.2	
207	Is robotic arm stereotactic body radiation therapy [virtual high dose rate brachytherapy] for prostate cancer? An analysis of comparative effectiveness using published data [corrected]. <i>Expert Review of Medical Devices</i> , 2015 , 12, 317-27	3.5	7
206	Modernizing Eligibility Criteria for Molecularly Driven Trials. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2815-20		59
205	Current clinical trials testing combinations of immunotherapy and radiation. <i>Seminars in Radiation Oncology</i> , 2015 , 25, 54-64	5.5	103
204	Evaluating the clinical impact of a genomic classifier in prostate cancer using individualized decision analysis. <i>PLoS ONE</i> , 2015 , 10, e0116866	3.7	9
203	Radiation therapy after radical prostatectomy for prostate cancer: evaluation of complications and influence of radiation timing on outcomes in a large, population-based cohort. <i>PLoS ONE</i> , 2015 , 10, e0118430	2.7	20
202	Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. <i>Journal of Clinical Oncology</i> , 2015 , 33, 944-51	2.2	151

201	African-american race is a predictor of seminal vesicle invasion after radical prostatectomy. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, e65-72	3.3	10
200	A novel biomarker signature to predict aggressive disease in African-American men with prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 24-24	2.2	
199	Molecular and clinical characterization of 1,577 primary prostate cancer tumors to reveal novel clinical and biological insights into its subtypes.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9-9	2.2	
198	Phase I trial of weekly cabazitaxel with concurrent intensity-modulated radiation therapy (IMRT) and androgen deprivation therapy (ADT) for the treatment of high-risk prostate cancer (PCa).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 26-26	2.2	
197	Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014 , 140, 573-82	4.9	26
196	Current status and recommendations for the future of research, teaching, and testing in the biological sciences of radiation oncology: report of the American Society for Radiation Oncology Cancer Biology/Radiation Biology Task Force, executive summary. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 88, 11-7	4	15
195	Polyacrylamide phantom for self-actuating needle-tissue interaction studies. <i>Medical Engineering and Physics</i> , 2014 , 36, 140-5	2.4	29
194	Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 89, 1038-1046	4	124
193	Large prostate gland size is not a contraindication to low-dose-rate brachytherapy for prostate adenocarcinoma. <i>Brachytherapy</i> , 2014 , 13, 456-64	2.4	5
192	A pilot study of hypofractionated stereotactic radiation therapy and sunitinib in previously irradiated patients with recurrent high-grade glioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 90, 369-75	4	19
191	The retinoblastoma tumor suppressor modulates DNA repair and radioresponsiveness. <i>Clinical Cancer Research</i> , 2014 , 20, 5468-5482	12.9	15
190	Vorinostat as a radiosensitizer for brain metastasis: a phase I clinical trial. <i>Journal of Neuro-Oncology</i> , 2014 , 118, 313-319	4.8	30
189	A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer. <i>Future Oncology</i> , 2014 , 10, 457-74	3.6	16
188	A model to predict deflection of bevel-tipped active needle advancing in soft tissue. <i>Medical Engineering and Physics</i> , 2014 , 36, 285-93	2.4	25
187	Study of Unrecovered Strain and Critical Stresses in One-Way Shape Memory Nitinol. <i>Journal of Materials Engineering and Performance</i> , 2014 , 23, 2885-2893	1.6	12
186	The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905. <i>PLoS ONE</i> , 2014 , 9, e94167	3.7	14
185	The Antiangiogenic Effects of a Vascular Endothelial Growth Factor Decoy Receptor Can Be Monitored in Vivo Using Contrast-Enhanced Ultrasound Imaging. <i>Molecular Imaging</i> , 2014 , 13, 7290.2013.000734	3.7	14
184	The quality frontier. <i>Future Oncology</i> , 2014 , 10, 563-7	3.6	

183	Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer?. <i>Expert Review of Anticancer Therapy</i> , 2014 , 14, 39-50	3.5	13
182	Path planning for robot-assisted active flexible needle using improved Rapidly-Exploring Random trees. <i>Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference</i> , 2014 , 2014, 380-3	0.9	2
181	Treatment-related complications of radiation therapy after radical prostatectomy: comparative effectiveness of intensity-modulated versus conformal radiation therapy. <i>Cancer Medicine</i> , 2014 , 3, 397-405	4.8	10
180	AAPM and GEC-ESTRO guidelines for image-guided robotic brachytherapy: report of Task Group 192. <i>Medical Physics</i> , 2014 , 41, 101501	4.4	59
179	RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SCHLAP1. <i>Lancet Oncology</i> , 2014 , 15, 1469-1480	21.7	192
178	Radiation protection of the gastrointestinal tract and growth inhibition of prostate cancer xenografts by a single compound. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 2968-77	6.1	10
177	Combining targeted agents with modern radiotherapy in soft tissue sarcomas. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	22
176	Development of a coordinated controller for robot-assisted shape memory alloy actuated needle for prostate brachytherapy. <i>Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference</i> , 2014 , 2014, 357-60	0.9	1
175	Minimizing morbidity in radiation oncology: a special issue from Future Oncology. <i>Future Oncology</i> , 2014 , 10, 2303-5	3.6	7
174	High-priority topics for cancer quality measure development: results of the 2012 American Society of Clinical Oncology Collaborative Cancer Measure Summit. <i>Journal of Oncology Practice</i> , 2014 , 10, e160-6	3.1	14
173	A tissue biomarker-based model that identifies patients with a high risk of distant metastasis and differential survival by length of androgen deprivation therapy in RTOG protocol 92-02. <i>Clinical Cancer Research</i> , 2014 , 20, 6379-88	12.9	10
172	microRNAs: The Short Link between Cancer and RT-Induced DNA Damage Response. <i>Frontiers in Oncology</i> , 2014 , 4, 133	5.3	7
171	Toward an improved understanding of the ionizing radiation induced DNA damage/response networks in human malignancies. <i>Frontiers in Oncology</i> , 2014 , 4, 335	5.3	
170	High dose rate brachytherapy boost for prostate cancer: a systematic review. <i>Cancer Treatment Reviews</i> , 2014 , 40, 414-25	14.4	48
169	The initial report of RTOG 0436: A phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for patients with esophageal cancer treated without surgery.. <i>Journal of Clinical Oncology</i> , 2014 , 32, LBA6-LBA6	2.2	14
168	A novel radiation-induced p53 mutation is not implicated in radiation resistance via a dominant-negative effect. <i>PLoS ONE</i> , 2014 , 9, e87492	3.7	2
167	Debio 1143, an antagonist of multiple inhibitor-of-apoptosis proteins, activates apoptosis and enhances radiosensitization of non-small cell lung cancer cells in vitro. <i>American Journal of Cancer Research</i> , 2014 , 4, 943-51	4.4	9
166	The antiangiogenic effects of a vascular endothelial growth factor decoy receptor can be monitored in vivo using contrast-enhanced ultrasound imaging. <i>Molecular Imaging</i> , 2014 , 13, 1-9	3.7	3

165	Leveraging RB status to define therapy for castrate-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 96-96	2.2	
164	The impact of body mass index on treatment recommendations for patients with intermediate risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 48-48	2.2	
163	Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610. <i>Radiation Oncology</i> , 2013 , 8, 100	4.2	14
162	Selectively starving cancer cells through dietary manipulation: methods and clinical implications. <i>Future Oncology</i> , 2013 , 9, 959-76	3.6	43
161	RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013 , 85, 1206-11	4	101
160	In reply to Franken and Barendsen. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013 , 86, 598-9	4	
159	Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4453-61	2.2	128
158	Evolution of advanced technologies in prostate cancer radiotherapy. <i>Nature Reviews Urology</i> , 2013 , 10, 565-79	5.5	51
157	Introduction: the changing landscape of prostate cancer. <i>Seminars in Oncology</i> , 2013 , 40, 241-3	5.5	
156	Phase I trials involving radiation therapy, quantifying the risks. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2013 , 57, 719-24	1.7	2
155	Impact of a radiation oncology elective on the careers of young physicians: update on a prospective cohort study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013 , 86, 214-5	4	10
154	Systematic review of hypofractionated radiation therapy for prostate cancer. <i>Cancer Treatment Reviews</i> , 2013 , 39, 728-36	14.4	47
153	The responsibilities of a chief resident in radiation oncology: results of a national survey. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013 , 87, 460-1	4	5
152	Stereotactic body radiation therapy for prostate cancer: is the technology ready to be the standard of care?. <i>Cancer Treatment Reviews</i> , 2013 , 39, 212-8	14.4	33
151	A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013 , 85, 321-8	4	37
150	Predictors of radiation oncology resident research productivity. <i>Journal of the American College of Radiology</i> , 2013 , 10, 185-9	3.5	32
149	Ribonucleotide reductase expression in cervical cancer: a radiation therapy oncology group translational science analysis. <i>International Journal of Gynecological Cancer</i> , 2013 , 23, 615-21	3.5	14
148	Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab. <i>Cancer Biology and Therapy</i> , 2013 , 14, 883-7	4.6	3

147	Nutrient restriction and radiation therapy for cancer treatment: when less is more. <i>Oncologist</i> , 2013 , 18, 97-103	5.7	35
146	Patterns of care for elderly men diagnosed with favorable-risk prostate cancer from 2004 to 2008: a population-based analysis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013 , 36, 606-11	2.7	9
145	A hormone-DNA repair circuit governs the response to genotoxic insult. <i>Cancer Discovery</i> , 2013 , 3, 1254-1264	11.4	215
144	ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 696-704	6.1	42
143	Prostate-specific antigen bounce predicts for a favorable prognosis following brachytherapy: a meta-analysis. <i>Journal of Contemporary Brachytherapy</i> , 2013 , 5, 210-4	1.9	12
142	Epidermal growth factor receptor mutation status and rad51 determine the response of glioblastoma to multimodality therapy with cetuximab, temozolomide, and radiation. <i>Frontiers in Oncology</i> , 2013 , 3, 13	5.3	9
141	NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 11-24	9.7	49
140	Dietary recommendations during and after cancer treatment: consistently inconsistent?. <i>Nutrition and Cancer</i> , 2013 , 65, 430-9	2.8	19
139	β integrins mediate resistance to ionizing radiation in vivo by inhibiting c-Jun amino terminal kinase 1. <i>Journal of Cellular Physiology</i> , 2013 , 228, 1601-9	7	36
138	Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer. <i>Expert Review of Medical Devices</i> , 2013 , 10, 751-63	3.5	7
137	Radiotherapy protocol deviations and clinical outcomes: a meta-analysis of cooperative group clinical trials. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 387-93	9.7	178
136	Using qualitative measures to improve quality in radiation oncology. <i>American Journal of Medical Quality</i> , 2013 , 28, 345-51	1.1	1
135	COX-2 expression and survival in patients with locally advanced cervical cancer treated with chemoradiotherapy and celecoxib: a quantitative immunohistochemical analysis of RTOG C0128. <i>International Journal of Gynecological Cancer</i> , 2013 , 23, 176-83	3.5	13
134	Commissioning and implementation of an implantable dosimeter for radiation therapy. <i>Journal of Applied Clinical Medical Physics</i> , 2013 , 14, 3989	2.3	3
133	Identifying barriers to patient acceptance of active surveillance: content analysis of online patient communications. <i>PLoS ONE</i> , 2013 , 8, e68563	3.7	19
132	Is comparative effectiveness research emphasized in oncologic residency training programs? Results of a national survey.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e17577-e17577	2.2	1
131	Vorinostat as a radiosensitizer for CNS malignancies: Preclinical results and phase I trial in brain metastasis.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2100-2100	2.2	
130	Impact of a novel decision counseling program on treatment knowledge, decisional conflict, and choice in men with early-stage, low-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9-9	2.2	

129	Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 83, e453-64	4	31
128	Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 82, 483-91	4	15
127	Physician beliefs and practices for adjuvant and salvage radiation therapy after prostatectomy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 82, e233-8	4	49
126	Can drugs enhance hypofractionated radiotherapy? A novel method of modeling radiosensitization using in vitro data. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 83, 385-93	4	25
125	Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignancies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 83, 1192-7	4	27
124	The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: a population-based analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 83, 1154-9	4	30
123	Implanted dosimeters identify radiation overdoses during IMRT for prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 83, e371-6	4	12
122	Radiotherapy improves survival in unresected stage I-III bronchoalveolar carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 84, 780-5	4	4
121	Quality assurance peer review chart rounds in 2011: a survey of academic institutions in the United States. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 84, 590-5	4	52
120	Assessing the value of an optional radiation oncology clinical rotation during the core clerkships in medical school. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 83, e465-9	4	23
119	Higher levels of c-Met expression and phosphorylation identify cell lines with increased sensitivity to AMG-458, a novel selective c-Met inhibitor with radiosensitizing effects. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 84, e525-31	4	16
118	Dual roles of PARP-1 promote cancer growth and progression. <i>Cancer Discovery</i> , 2012 , 2, 1134-49	24.4	260
117	Prognostic factors and outcomes after definitive treatment of female urethral cancer: a population-based analysis. <i>Urology</i> , 2012 , 80, 374-81	1.6	36
116	Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling. <i>European Journal of Cancer</i> , 2012 , 48, 837-44	7.5	112
115	Reply letter to: Salvage radiotherapy: A plea for dose-escalation with intensity modulated radiotherapy. <i>European Journal of Cancer</i> , 2012 , 48, 1414	7.5	
114	Gene expression signatures modulated by epidermal growth factor receptor activation and their relationship to cetuximab resistance in head and neck squamous cell carcinoma. <i>BMC Genomics</i> , 2012 , 13, 160	4.5	24
113	Salvage radiotherapy for prostate cancer: Finding a way forward using radiobiological modeling. <i>Cancer Biology and Therapy</i> , 2012 , 13, 1449-53	4.6	1
112	Biomarkers of aging and radiation therapy tailored to the elderly: future of the field. <i>Seminars in Radiation Oncology</i> , 2012 , 22, 334-8	5.5	10

111	Reirradiation of recurrent meningioma. <i>Journal of Clinical Neuroscience</i> , 2012 , 19, 1261-4	2.2	23
110	Fractionated stereotactic radiation therapy improves cranial neuropathies in patients with skull base meningiomas: a retrospective cohort study. <i>Radiation Oncology</i> , 2012 , 7, 225	4.2	5
109	Re-implantation of suboptimal prostate seed implantation: technique with intraoperative treatment planning. <i>Journal of Contemporary Brachytherapy</i> , 2012 , 4, 176-81	1.9	1
108	Improving prognosis of glioblastoma in the 21st century: who has benefited most?. <i>Cancer</i> , 2012 , 118, 4228-34	6.4	39
107	Characterization and outcomes of optic nerve gliomas: a population-based analysis. <i>Journal of Neuro-Oncology</i> , 2012 , 107, 591-7	4.8	34
106	Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. <i>BJU International</i> , 2012 , 109 Suppl 1, 22-9	5.6	330
105	Pilot study of meaningful use of electronic health records in radiation oncology. <i>Journal of Oncology Practice</i> , 2012 , 8, 219-23	3.1	12
104	mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer. <i>Endocrine-Related Cancer</i> , 2012 , 19, 1-12	5.7	44
103	Comparative effectiveness research for prostate cancer radiation therapy: current status and future directions. <i>Future Oncology</i> , 2012 , 8, 37-54	3.6	12
102	The quality of cervical cancer brachytherapy implantation and the impact on local recurrence and disease-free survival in radiation therapy oncology group prospective trials 0116 and 0128. <i>International Journal of Gynecological Cancer</i> , 2012 , 22, 123-31	3.5	76
101	A novel curvilinear approach for prostate seed implantation. <i>Medical Physics</i> , 2012 , 39, 1887-92	4.4	38
100	Towards a Nitinol Actuator for an Active Surgical Needle 2012 ,		8
99	Radiotherapy protocol deviations and clinical outcomes: A meta-analysis of cooperative group clinical trials.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 181-181	2.2	2
98	Feasibility of dietary intervention in a breast cancer population.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e11505-e11505	2.2	
97	Multidisciplinary management and use of neoadjuvant cisplatin combination chemotherapy in patients with muscle-invasive urothelial bladder cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e15012-e15012		2
96	Natural language processing (NLP) of Internet conversations to evaluate prostate cancer (PC) patients' perceptions of active surveillance (AS).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 14-14	2.2	
95	Radiation-Induced Toxicity and Radiation Response Modifiers in Zebrafish 2011 , 295-306		
94	Potential for dose escalation in the postprostatectomy setting with intensity-modulated radiation therapy: a dosimetric study using EORTC consensus guidelines for target volume contours. <i>Practical Radiation Oncology</i> , 2011 , 1, 105-14	2.8	9

93	Post-prostatectomy image-guided radiation therapy: evaluation of toxicity and inter-fraction variation using online cone-beam CT. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2011 , 55, 507-157	1.7	9
92	Reliability of EUCLIDIAN: an autonomous robotic system for image-guided prostate brachytherapy. <i>Medical Physics</i> , 2011 , 38, 96-106	4.4	10
91	Evaluation of nuclear factor B and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610. <i>BJU International</i> , 2011 , 108, E51-8	5.6	19
90	Cediranib enhances control of wild type EGFR and EGFRVIII-expressing gliomas through potentiating temozolomide, but not through radiosensitization: implications for the clinic. <i>Journal of Neuro-Oncology</i> , 2011 , 105, 181-90	4.8	13
89	A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies. <i>Cancer</i> , 2011 , 117, 5548-59	6.4	27
88	In reply to Dr. King (Adjuvant radiotherapy after prostatectomy: does waiting for a detectable prostate-specific antigen level make sense?). <i>International Journal of Radiation Oncology Biology Physics</i> , 2011 , 80, 1279	4	
87	Postprostatectomy radiation therapy: an evidence-based review. <i>Future Oncology</i> , 2011 , 7, 1429-40	3.6	12
86	A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity. <i>Circulation Research</i> , 2011 , 109, 1401-9	15.7	67
85	Decreasing the adverse effects of cancer therapy: National Cancer Institute guidance for the clinical development of radiation injury mitigators. <i>Clinical Cancer Research</i> , 2011 , 17, 222-8	12.9	28
84	The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments. <i>Cell Cycle</i> , 2011 , 10, 2497-503	4.7	186
83	Patient-oriented cancer information on the internet: a comparison of wikipedia and a professionally maintained database. <i>Journal of Oncology Practice</i> , 2011 , 7, 319-23	3.1	64
82	Enhancing prostate cancer care through the multidisciplinary clinic approach: a 15-year experience. <i>Journal of Oncology Practice</i> , 2010 , 6, e5-e10	3.1	68
81	Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3048-53	2.2	251
80	Smart Needling System for Fully Conformal Radiation Dose Delivery in Treating Prostate Cancer 2010 ,		3
79	Radiation dose-volume effects in the brain. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010 , 76, S20-7	4	506
78	A comparison of preplan transrectal ultrasound with preplan-CT in assessing volume and number of seeds needed for real-time ultrasound-based intra-operative planning in prostate (125)I seed implantation. <i>Brachytherapy</i> , 2010 , 9, 335-40	2.4	8
77	Phase I trial using patupilone (epothilone B) and concurrent radiotherapy for central nervous system malignancies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010 , 77, 1009-16	4	24
76	Biomarkers and surrogate endpoints for normal-tissue effects of radiation therapy: the importance of dose-volume effects. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010 , 76, S145-50	4	55

75	Differential regulation of p53 function by the N-terminal Δp53 and Δ13p53 isoforms in zebrafish embryos. <i>BMC Developmental Biology</i> , 2010 , 10, 102	3.1	20
74	Assessment of Epidermal Growth Factor Receptor (EGFR) expression in human meningioma. <i>Radiation Oncology</i> , 2010 , 5, 46	4.2	27
73	Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4281-6	2.2	67
72	Changes in gene expression predicting local control in cervical cancer: results from Radiation Therapy Oncology Group 0128. <i>Clinical Cancer Research</i> , 2009 , 15, 4199-206	12.9	12
71	Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341). <i>Archives of Gynecology and Obstetrics</i> , 2009 , 279, 41-6	2.5	27
70	Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009 , 74, 433-9	4	72
69	Combination of vandetanib, radiotherapy, and irinotecan in the LoVo human colorectal cancer xenograft model. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009 , 75, 854-61	4	11
68	Effect of percentage of positive prostate biopsy cores on biochemical outcome in low-risk PCa treated with brachytherapy or 3D-CRT. <i>Urology</i> , 2009 , 73, 1328-34	1.6	10
67	Technique of outpatient placement of intraprostatic fiducial markers before external beam radiotherapy. <i>Urology</i> , 2009 , 73, 881-6	1.6	30
66	Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. <i>Gastroenterology</i> , 2009 , 136, 187-95	13.3	331
65	Nuclear factor kappaB inhibitors alleviate and the proteasome inhibitor PS-341 exacerbates radiation toxicity in zebrafish embryos. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 2625-34	6.1	29
64	Distinguishing post-treatment changes from recurrent disease in cholangiocarcinoma: a case report. <i>Journal of Medical Case Reports</i> , 2008 , 2, 76	1.2	
63	Combined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma. <i>Clinical Cancer Research</i> , 2008 , 14, 5466-75	12.9	28
62	Hypoxia in prostate cancer: observation to intervention. <i>Lancet Oncology, The</i> , 2008 , 9, 308-9	21.7	11
61	Inhibition of p73 function by Pifithrin-alpha as revealed by studies in zebrafish embryos. <i>Cell Cycle</i> , 2008 , 7, 1224-30	4.7	24
60	Epidermal growth factor receptor blockade in combination with conventional chemotherapy inhibits soft tissue sarcoma cell growth in vitro and in vivo. <i>Clinical Cancer Research</i> , 2008 , 14, 2785-95	12.9	32
59	Soft tissue sarcoma cells are highly sensitive to AKT blockade: a role for p53-independent up-regulation of GADD45 alpha. <i>Cancer Research</i> , 2008 , 68, 2895-903	10.1	45
58	Biologically conformal treatment: biomarkers and functional imaging in radiation oncology. <i>Future Oncology</i> , 2008 , 4, 689-704	3.6	9

57	Normalization of Tumor Vasculature and Improvement of Radiation Response by Antiangiogenic Agents 2008 , 311-321		1
56	A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007 , 67, 104-9	4	43
55	VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007 , 67, 1526-37	4	115
54	Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007 , 69, 111-7	4	28
53	Strategic plans to promote head and neck cancer translational research within the radiation therapy oncology group: a report from the translational research program. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007 , 69, S67-78	4	12
52	Gene expression profiles as markers of aggressive disease-EGFR as a factor. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007 , 69, S102-5	4	6
51	Uncemented total hip arthroplasty in patients with a history of pelvic irradiation for prostate cancer. <i>Journal of Bone and Joint Surgery - Series A</i> , 2007 , 89, 798-805	5.6	22
50	COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. <i>Lancet Oncology, The</i> , 2007 , 8, 912-20	21.7	88
49	Malignant transformation of immortalized HaCaT keratinocytes through deregulated nuclear factor kappaB signaling. <i>Cancer Research</i> , 2006 , 66, 5209-15	10.1	50
48	In vivo radioprotection by the fullerene nanoparticle DF-1 as assessed in a zebrafish model. <i>Clinical Cancer Research</i> , 2006 , 12, 7086-91	12.9	152
47	Antisense inhibition of cyclin D1 expression is equivalent to flavopiridol for radiosensitization of zebrafish embryos. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006 , 66, 546-51	4	23
46	Novel use of zebrafish as a vertebrate model to screen radiation protectors and sensitizers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005 , 61, 10-3	4	84
45	Involvement of the Fhit gene in the ionizing radiation-activated ATR/CHK1 pathway. <i>Journal of Cellular Physiology</i> , 2005 , 202, 518-23	7	46
44	CHK1 affects cell sensitivity to microtubule-targeted drugs. <i>Journal of Cellular Physiology</i> , 2005 , 203, 273-6	7	9
43	Salvage of suboptimal prostate seed implantation: Reimplantation of underdosed region of prostate base. <i>Brachytherapy</i> , 2005 , 4, 163-70	2.4	15
42	Coordinate control of cell cycle regulatory genes in zebrafish development tested by cyclin D1 knockdown with morpholino phosphorodiamidates and hydroxypropyl-phosphono peptide nucleic acids. <i>Nucleic Acids Research</i> , 2005 , 33, 4914-21	20.1	34
41	Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. <i>Clinical Cancer Research</i> , 2005 , 11, 835-42	12.9	80
40	Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer. <i>Clinical Cancer Research</i> , 2004 , 10, 3927-33	12.9	50

39	Reanalysis of cancer drugs: old drugs, new tricks. <i>Clinical Cancer Research</i> , 2004 , 10, 3897-907	12.9	24
38	Factors predicting for urinary incontinence after prostate brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004 , 59, 1395-404	4	28
37	Targeting the EGFR in neoplasia--more questions than answers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004 , 58, 899-902	4	2
36	The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004 , 58, 927-31	4	108
35	Improving tumor response to radiotherapy by targeting angiogenesis signaling pathways. <i>Hematology/Oncology Clinics of North America</i> , 2004 , 18, 1039-57, viii	3.1	34
34	. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003 , 26, S75-S80	2.7	5
33	. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003 , 26, S46-S47	2.7	3
32	. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003 , 26, S98-S102	2.7	2
31	Targeting angiogenic processes by combination low-dose paclitaxel and radiation therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003 , 26, e45-53	2.7	11
30	Cyclooxygenase-2 (COX-2) expression in human meningioma as a function of tumor grade. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003 , 26, S98-102	2.7	21
29	A detailed examination of the difference between planned and treated margins in 125I permanent prostate brachytherapy. <i>Brachytherapy</i> , 2003 , 2, 223-8	2.4	7
28	Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). <i>International Journal of Cancer</i> , 2003 , 104, 121-9	7.5	179
27	Probability of late rectal morbidity in 125I prostate brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003 , 55, 342-53	4	93
26	Is it necessary to eliminate the posterior dose margin in prostate brachytherapy to achieve an acceptably low risk of late rectal morbidity?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003 , 57, 293-9	4	3
25	The safety and tolerability of low-dose irradiation for the management of gynaecomastia caused by antiandrogen monotherapy. <i>Lancet Oncology, The</i> , 2003 , 4, 30-6	21.7	39
24	Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. <i>Clinical Cancer Research</i> , 2003 , 9, 1957-71	12.9	241
23	Impact of postimplant edema on V(100) and D(90) in prostate brachytherapy: can implant quality be predicted on day 0?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002 , 53, 610-21	4	46
22	Comparing contrast-enhanced ultrasound to immunohistochemical markers of angiogenesis in a human melanoma xenograft model: preliminary results. <i>Ultrasound in Medicine and Biology</i> , 2002 , 28, 445-51	3.5	45

21	Dosimetric analysis of urinary morbidity following prostate brachytherapy (125I vs. 103Pd) combined with external beam radiation therapy. <i>International Journal of Cancer</i> , 2001 , 96 Suppl, 83-8	7.5	9
20	Does hormonal therapy influence sexual function in men receiving 3D conformal radiation therapy for prostate cancer?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001 , 50, 591-5	4	35
19	Can extraprostatic extension be treated by prostate brachytherapy? An analysis based on postimplant dosimetry. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001 , 51, 1196-9	4	30
18	Elevated COX-2 expression in cervical carcinoma: reduced cause-specific survival and pelvic control. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2001 , 24, 443-6	2.7	42
17	Targeting angiogenic processes by combination rofecoxib and ionizing radiation. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2001 , 24, 438-42	2.7	75
16	The impact of postimplant edema on the urethral dose in prostate brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000 , 47, 661-4	4	21
15	The impact of edema on planning 125I and 103Pd prostate implants. <i>Medical Physics</i> , 1999 , 26, 763-7	4.4	57
14	A dynamic model for the estimation of optimum timing of computed tomography scan for dose evaluation of 125I or 103Pd seed implant of prostate. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999 , 43, 447-54	4	50
13	Variation of clinical target volume definition in three-dimensional conformal radiation therapy for prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999 , 44, 931-5	4	67
12	The efficacy of early adjuvant radiation therapy for pT3N0 prostate cancer: a matched-pair analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999 , 45, 53-8	4	77
11	Effect of post-implant edema on the rectal dose in prostate brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999 , 45, 571-6	4	39
10	Optimum timing for image-based dose evaluation of 125I and 103PD prostate seed implants. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999 , 45, 1063-72	4	43
9	Edema associated with I-125 or Pd-103 prostate brachytherapy and its impact on post-implant dosimetry: an analysis based on serial CT acquisition. <i>International Journal of Radiation Oncology Biology Physics</i> , 1998 , 41, 1069-77	4	196
8	The effect of treatment positioning on normal tissue dose in patients with prostate cancer treated with three-dimensional conformal radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997 , 37, 13-9	4	72
7	Effect of edema on the post-implant dosimetry of an I-125 prostate implant: a case study. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997 , 38, 335-9	4	62
6	Calcium-dependent translocation of sorcin to membranes: functional relevance in contractile tissue. <i>FEBS Letters</i> , 1995 , 357, 230-4	3.8	60
5	Ab initio studies of aromatic-aromatic and aromatic-polar interactions in the binding of substrate and inhibitor to dihydrofolate reductase. <i>International Journal of Peptide and Protein Research</i> , 1992 , 39, 18-23		13
4	Mutational analysis of human NRAS genes in malignant melanoma: rapid methods for oligonucleotide hybridization and manual and automated direct sequencing of products generated by the polymerase chain reaction. <i>Genes Chromosomes and Cancer</i> , 1990 , 1, 257-69	5	23

- 3 Dihydrofolate reductase as a therapeutic target. *FASEB Journal*, **1990**, 4, 2441-52 0.9 277
- 2 Noninvasive detection of left ventricular dysfunction with a portable electrocardiographic gated scintillation probe device. *American Journal of Cardiology*, **1981**, 47, 610-7 3 41
- 1 Utilizing Digital Health to Collect Electronic Patient-Reported Outcomes in Prostate Cancer: Single-Arm Pilot Trial (Preprint) 1